Olaparib in patients with BRCA-related cancers

Olaparib produced a tumour response rate of 26.2% in several advanced cancer types associated with BRCA1 and BRCA2 mutations. The response rate provides new hope for patients with ovarian, breast, pancreatic and prostate cancers whose disease has not responded to standard therapies. Results of the phase II study are published online in the Journal of Clinical Oncology. Read more here.